A Head-to-head Comparative Study of 18F-PSMA-1007 PET/CT and 18F-FDG PET/CT Imaging in Multiple Myeloma
Status:
Recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
Multiple myeloma (MM) is the second most common hematological malignancy and is still
incurable. Positron emission tomography/computed tomography (PET/CT) has been used to
diagnose, assess treatment response, and predict prognosis in MM. 18F-fluorodeoxyglucose
(FDG) is the most widely used radiotracer, but there is heterogeneous uptake in MM, that is,
uptake is negative in some myeloma cells. There are currently reports of cases with strong
uptake of prostate-specific membrane antigen (PSMA) PET/CT in MM. Therefore, this preliminary
study was designed to compare the imaging results of 18F-PSMA-1007 PET/CT and 18F-FDG PET/CT,
and to evaluate the additional value of 18F-PSMA-1007 PET/CT to 18F-FDG PET/CT in MM.